Flatiron announces clinical decision support application through Epic’s App Orchard

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Flatiron Health announced the availability of its clinical decision support and pathways application, Flatiron Assist, in the App Orchard.

Flatiron Assist supports oncologists in selecting therapies in line with best clinical practices, including the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, and in identifying potentially relevant clinical trials.

The integrated regimen selection workflow allows clinicians to quickly confirm the clinical data needed to determine adherence to guidelines. Health system administrators can use the clinical data collected by this tool to streamline the prior authorization process, measure variation in care across a practice or health system, and report pathways compliance to payers.

“The rapidly evolving treatment landscape and increasing payer reporting requirements make it challenging for busy oncologists to efficiently get the best treatments to their patients,” James Hamrick, senior medical director, Flatiron Health, said in a statement. “Flatiron Assist is an EHR-integrated tool that puts the doctor and the patient at the forefront, enabling evidence-based treatment selection, efficient payer authorization, and insight into care patterns across practices and health systems.”

Available now in the App Orchard, Flatiron Assist is a SMART on FHIR application that will launch from the patient’s chart in Epic, eliminating the need for duplicate data entry outside the electronic medical record. Flatiron Assist pulls available demographics, diagnosis, and cancer-specific data, such as staging, from Epic and, based on those inputs, surfaces evidence-based therapy options and clinical trials for each patient. Once the oncologist chooses a treatment regimen in Flatiron Assist™, the selected regimen is automatically opened in Epic.

“Integrating NCCN’s recommendations into point-of-care apps like Flatiron Assist puts the latest evidence and multidisciplinary expert knowledge at the fingertips of oncologists everywhere,” Robert W. Carlson, CEO of NCCN, said in a statement. “NCCN Guidelines are the most frequently updated medical guidelines in any discipline; they should also be the most accessible. The convenience of Flatiron Assist can give doctors more time to engage in shared decision making in order to determine which guideline-concordant treatment plan offers the most benefit.”

Additional information is available here, and here.

Table of Contents

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login